Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587805 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,672
- Enrollment target
NCT03587805: Completed Phase 3 study, sponsored by LEO Pharma.
NCT03587805 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 1,672 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587805, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,672 participants
- Enrollment target
Study Summary
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Interventions
- DRUG Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,672 participants |
| Start Date | 2018-03-18 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 3 |
What the finished NCT03587805 record still lists
NCT03587805 is an interventional study that assigns participants to a tested intervention. Its 1,672 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 1 intervention - of which Tralokinumab is the first listed.
NCT03587805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03587805 about?
NCT03587805 is a clinical study titled "Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND". The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
What is the current status of trial NCT03587805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,672 participants. The study started on 2018-03-18. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT03587805?
The interventions under investigation include: Tralokinumab (DRUG).
Who is sponsoring clinical trial NCT03587805?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03587805's enrollment target sits among peer trials
1,672 136th of 2000 higher than 1,865 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI